94 related articles for article (PubMed ID: 19878494)
1. A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approach.
Madan J; Rawdin A; Stevenson M; Tappenden P
Value Health; 2010; 13(2):215-21. PubMed ID: 19878494
[TBL] [Abstract][Full Text] [Related]
2. Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales.
Rafia R; Brennan A; Madan J; Collins K; Reed MW; Lawrence G; Robinson T; Greenberg D; Wyld L
Value Health; 2016 Jun; 19(4):404-12. PubMed ID: 27325332
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
[TBL] [Abstract][Full Text] [Related]
4. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program.
Rim SH; Allaire BT; Ekwueme DU; Miller JW; Subramanian S; Hall IJ; Hoerger TJ
Cancer Causes Control; 2019 Aug; 30(8):819-826. PubMed ID: 31098856
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance target for community-based breast cancer screening in China: a model simulation.
Yang L; Wang J; Cheng J; Wang Y; Lu W
BMC Cancer; 2018 Mar; 18(1):261. PubMed ID: 29514679
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cost-effectiveness analysis of screening mammography.
Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women.
Barfar E; Rashidian A; Hosseini H; Nosratnejad S; Barooti E; Zendehdel K
Arch Iran Med; 2014 Apr; 17(4):241-5. PubMed ID: 24724599
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
13. What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420).
French DP; Astley S; Brentnall AR; Cuzick J; Dobrashian R; Duffy SW; Gorman LS; Harkness EF; Harrison F; Harvie M; Howell A; Jerrison A; Machin M; Maxwell AJ; McWilliams L; Payne K; Qureshi N; Ruane H; Sampson S; Stavrinos P; Thorpe E; Ulph F; van Staa T; Woof V; Evans DG
BMC Cancer; 2020 Jun; 20(1):570. PubMed ID: 32552763
[TBL] [Abstract][Full Text] [Related]
14. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of breast cancer screening programme for women in rural China.
Sun L; Sadique Z; Dos-Santos-Silva I; Yang L; Legood R
Int J Cancer; 2019 May; 144(10):2596-2604. PubMed ID: 30367451
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of an organized breast cancer screening program in Southern Brazil].
Ribeiro RA; Caleffi M; Polanczyk CA
Cad Saude Publica; 2013 Nov; 29 Suppl 1():S131-45. PubMed ID: 25402242
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of testing for breast cancer susceptibility genes.
Holland ML; Huston A; Noyes K
Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
[TBL] [Abstract][Full Text] [Related]
19. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
20. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.
Rojnik K; Naversnik K; Mateović-Rojnik T; Primiczakelj M
Value Health; 2008; 11(2):139-48. PubMed ID: 18380626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
